Oral insulin for diabetes prevention in NOD mice: Potentiation by enhancing Th2 cytokine expression in the gut through bacterial adjuvant

Diabetologia

Volumn 40, Issue 8, 1997, Pages 902-909

  Hartmann, B ^a,b   Bellmann, K ^a   Ghiea, I ^a   Kleemann, R ^a   Kolb, H ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Antigen presenting cells; Diabetes mellitus; Mucosal immunology; Oral tolerance; Th2 cytokines

Indexed keywords

INSULIN; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE; NITRITE; OM 89; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; MACROPHAGE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, BACTERIAL; CELL LINE; COHORT STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MACROPHAGES; MICE; MICE, INBRED NOD; NITRIC OXIDE SYNTHASE; RANDOM ALLOCATION; TH2 CELLS; TIME FACTORS;

EID: 0030805783     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050766     Document Type: Article

References (42)

1. Castano L, Eisenbarth GS (1990) Type-1 diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 8: 647-679
2. Rossini A, Mordes JP, Greiner DL (1989) The pathogenesis of autoimmune diabetes mellitus. Curr Opinion Immunol 2: 598-603
3. Rothe H, Faust A, Schade U Kleemann R, Bosse G, Hibino T, Martin S, Kolb H (1994) Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not of interleukin-4. Diabetologia 37: 1154-1158
4. Rabinovitch A (1994) Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM-therapeutic intervention by immunostimulation? Diabetes 43: 613-621
5. Pennline KJ, Roque-Gaffney E, Monahan M (1994) Recombinant human IL-10 prevents the onset of diabetes in NOD mice. Clin Immunol and Immunopathol 71: 169-175
6. Rapoport MJ, Jaramillo A, Zipris D et al. (1993) IL-4 reverses T-cell proliferative unresponsiveness and prevents the onset of diabetes in NOD mice. J Exp Med 178: 87-99
7. Shehadeh NN, LaRosa F, Lafferty KJ (1993) Altered cytokine activity in adjuvant inhibition of autoimmune diabetes. J Autoimm 6: 291-300
8. Muir A, Schatz D, Maclaren N (1993) Antigen specific immunotherapy: oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetes. Diabetes Metab Rev 9: 279-287
9. Thompson HSG, Staines NA (1986) Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin Exp Immunol 64: 581-586
10. Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke FJ (1986) Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 83: 7443-7446
11. Higgins P, Weiner HL (1988) Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 140: 440-445
12. Miller A, Lider O, Weiner HL (1991) Antigen driven bystander suppression following oral administration of antigens. J Exp Med 174: 791-798
13. Weiner HL, Friedmann A, Miller A et al. (1994) Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 12: 809-837
14. Husby S, Mestecky J, Moldoveanu Z, Holland S, Elson CH (1994) Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol 152: 4663
15. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL (1991) Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Nat Acad Sci USA 88: 10252-10256
16. Bergerot I, Fabien N, Maguer V, Thivolet C (1994) Oral administration of human insulin to NOD mice generates CD4 (+) T cells that suppress adoptive transfer of diabetes. J Autoimmun 7: 655-663
17. Hancock WW, Polanski M, Zhang J, Blogg N, Weiner HL (1995) Suppression of insulitis in non-obese Diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-b, and prostaglandin-E. Am J Pathol 147: 1193-1199
18. Khoury SJ, Hancock WW, Weiner HL (1992) Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 176: 1355-1364
19. Murakami M, Tsubata T, Shinkura R et al. (1994) Oral administration of lipopolysaccharides activates B-1 cells in the peritoneal cavity and lamina propria of the gut and induces autoimmune symptoms in an autoantibody transgenic mouse. J Exp Med 180: 111-121
20. Peters DH, Goa KL (1994) OM-8980 - an initial review of its pharmacology and therapeutic potential in rheumatoid arthritis. Clin Immunother 2: 65-67
21. Polla BS, Baladi S, Fuller K, Rook G (1995) Presence of hsp65 in bacterial extracts (OM-89): a possible mediator of orally-induced tolerance? Experientia 51: 775-779
22. Kiesel U (1994) Prevention of diabetes in BB rats by an E. coli extract (OM-89). Int J Immunopathol Pharmacol 7: 193-199
23. Tammen H, The German urinary tract infection study group (1990) Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. Brit J Urol 65: 6-9
24. Rothe H, Burkart V, Faust A, Kolb H (1996) IL-12 gene expression is associated with rapid development of diabetes mellitus in non-obese diabetic mice. Diabelotogia 39: 119-122
25. Kleemann R, Rothe H, Kolb-Bachofen V, Xie Q-W. Nathan C, Martin S, Kolb H (1993) Transcription and translation of inducible nitric oxide synthase in the pancreas of prediabetic BB rats. FEBS Lett 328: 9-12
26. Kröncke K-D, Kolb-Bachofen V, Berschick B, Burkart V, Kolb H (1991) Activated macrophages kill pancreatic syngeneic islet cells via arginine-dependent nitric oxide generation. Biochem Biophys Res Commun 175: 752-758
27. Unglaub R, Maxeiner B, Thoma B, Pfizenmeier K, Scheurich P (1987) Downregulation of tumor necrosis factor sensitivity via modulation of TNF binding capacity by protein kinase C activators. J Exp Med 166: 1788-1797
28. Zhang X, Giangreco L, Broome HE, Dargan CM, Swain SL (1995) Control of CD4 effector fate: transforming growth factor b1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. J Exp Med 182: 699-709
29. Kay WA, Adri MNS, Soeldner JS et al. (1986) Acquired defect in interleukin-2 production in patients with type I diabetes mellitus. New Engl J Med 315: 920-925
30. Lang F, Pogu S, Maurel C, Charbonnel B, Sai P (1987) Production of and response to interleukin 2 by blood mononuclear cells from some type I diabetic patients. Diabetes Metabolism 13: 37-43
31. Prud'homme GJ, Fuks A, Colle E, Seemayer TA, Guttmann RD (1984) Immune dysfunction in diabetes-prone BB rats. Interleukin 2 production and other mitogen-induced responses are suppressed by activated macrophages. J Exp Med 159:463-478
32. Zier KS, Leo MM, Spielmann RS, Baker L (1984) Decreased synthesis of interleukin 2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes 33:552-555
33. Zielaseck J, Burkart V, Naylor P, Goldstein A, Kiesel U, Kolb H (1990) Interleukin-2-dependent control of disease development in spontaneously diabetic BB rats. Immunology 69:209-214
34. von Herrath MG, Allison J, Miller JFAP, Oldstone MBA (1995) Focal expression of interleukin-2 does not break unresponsiveness to "self" (viral) antigen expressed in b cells but enhances development of autoimmune disease (diabetes) after initiation of an anti-self immune response. J Clin Invest 95: 477-485
35. Blanas E, Carbone FR, Allison J, Miller JFAP, Heath WR (1996) Induction of autoimmune diabetes by oral administration of autoantigen. Science 274: 1707-1709
36. Meyer AL, Benson JM, Gienapp IE, Cox KL, Whitacre CC (1996) Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. J Immunol 157: 4230-4238
37. Severn A, Xu D, Doyle J et al. (1993) Pre-exposure of murine macrophages to lipopolysaccharide inhibits the induction of nitric oxide synthase and reduces leishmanicidal activity. Eur J Immunol 23: 1711-1714
38. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA (1996) Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 98: 70-77
39. Bessler WG, Beck P, Konetznick U et al. (1991) Biological activity of bacterial surface components. Immunogenicity and immunomodulatory properties of bacterial extract from Escherichia coli. Arzneim-Forsch/Drug Res 41: 274-279
40. Bottex C, Cristau B, Corazza JL, Mougin B, Fontanges R (1988) Effects of two bacterial extracts, OM-89 and Broncho-Vaxom, on IL-1 release and metabolic activity of a murine macrophage cell-line. Int J Immunotherapy 4:203-212
41. Pham TV, Kreis B, Corradin-Betz S, Bauer J, Mauel J (1990) Metabolic and functional stimulation of lymphocytes and macrophages by an Escherichia coli extract (OM-89): in vitro studies. J Biol Resp Mod 9: 231-240
42. Ziegler-Heitbrock HWL (1995) Molecular mechanism in tolerance to lipopolysaccharide. J Inflamm 45: 13-26